Cabozantinib in renal cell carcinoma: only a METEOR or a rising star?

Cabozantinib in renal cell carcinoma: only a METEOR or a rising star?

Authors

  • Melissa Bersanelli University Hospital of Parma
  • Sebastiano Buti University Hospital of Parma

Keywords:

Renal cell carcinoma, Cabozantinib, METEOR, TKI

Abstract

N/A (Letter to the Editor)

Downloads

Published

13-09-2016

Issue

Vol. 87 No. 2 (2016): Acta BioMed 2-2016

Section

LETTERS TO EDITOR

License

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. 
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

How to Cite

1.
Bersanelli M, Buti S. Cabozantinib in renal cell carcinoma: only a METEOR or a rising star?. Acta Biomed [Internet]. 2016 Sep. 13 [cited 2024 Jul. 27];87(2):224-5. Available from: https://mattioli1885journals.com/index.php/actabiomedica/article/view/5151